## Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

HEMISPHER Form 4 August 02, 20	RX BIOPHARM	A INC									
								OMB A	PPROVAL	L	
FORM	UNITED	STATES		RITIES Anshington			COMMISSION		3235-0		
Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru- 1(b).	er <b>STATEN</b> 5. Filed pur <sup>s</sup> Section 17(	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								January 31, 2005 d average burs per 0.5	
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> KIANI IRAJ EGHBAL			2. Issuer Name <b>and</b> Ticker or Trading Symbol HEMISPHERX BIOPHARMA INC [HEB]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) 18800 DELWARE ST, SUITE 900			3. Date of Earliest Transaction (Month/Day/Year) 08/02/2013			X_ Director 10% Owner Officer (give title below) Other (specify below)					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>					
HUNTINGT	ON BEACH, C.	A 92648						More than One R			
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned		
	2. Transaction Date Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature o Indirect Beneficial Ownership (Instr. 4)	l	
Reminder: Repo	ort on a separate line	for each cl	ass of sec	urities bene:	Perso inform requir	ns who rest nation cont ed to resp ys a curre	or indirectly. spond to the colle tained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Disposed o	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Options to buy Common Stock	\$ 0.25	08/02/2013		J <u>(1)</u>	150,000		08/02/2013	08/02/2023	Common Stock	150,00

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
KIANI IRAJ EGHBAL 18800 DELWARE ST SUITE 900 HUNTINGTON BEACH	, CA 92648	X					
Signatures							
Iraj Eghbal Kiani	08/02/201	3					
<b>**</b> Signature of	Date						

## **Explanation of Responses:**

Reporting Person

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Stock Options issued as a result of a Board resolution to grant 150,000 shares to each member of the Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.